These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9557719)

  • 41. Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon.
    Gerotto M; Dal Pero F; Pontisso P; Noventa F; Gatta A; Alberti A
    Gastroenterology; 2000 Dec; 119(6):1649-55. PubMed ID: 11113086
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.
    Shen C; Hu T; Shen L; Gao L; Xie W; Zhang J
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1898-903. PubMed ID: 17914967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.
    Puig-Basagoiti F; Sáiz JC; Forns X; Ampurdanès S; Giménez-Barcons M; Franco S; Sánchez-Fueyo A; Costa J; Sánchez-Tapias JM; Rodés J
    J Med Virol; 2001 Sep; 65(1):35-44. PubMed ID: 11505441
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.
    El-Shamy A; Hotta H
    World J Gastroenterol; 2014 Jun; 20(24):7555-69. PubMed ID: 24976696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection.
    Murakami T; Enomoto N; Kurosaki M; Izumi N; Marumo F; Sato C
    Hepatology; 1999 Oct; 30(4):1045-53. PubMed ID: 10498658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin.
    Cappiello G; Abbate I; Lo Iacono O; Longo R; Solmone M; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxi A; Ippolito G; Capobianchi MR
    Antivir Ther; 2003 Apr; 8(2):105-10. PubMed ID: 12741622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
    Chambers TJ; Fan X; Droll DA; Hembrador E; Slater T; Nickells MW; Dustin LB; Dibisceglie AM
    J Virol; 2005 Mar; 79(5):3071-83. PubMed ID: 15709027
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.
    Pawlotsky JM; Germanidis G; Frainais PO; Bouvier M; Soulier A; Pellerin M; Dhumeaux D
    J Virol; 1999 Aug; 73(8):6490-9. PubMed ID: 10400744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Substitutions in interferon sensitivity-determining region and hepatocarcinogenesis after hepatitis C virus eradication.
    Yasuda S; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Toyoda H; Kumada T; Hirooka Y; Goto H
    J Gastroenterol Hepatol; 2018 Nov; 33(11):1904-1911. PubMed ID: 29744922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.
    Kobayashi M; Watanabe K; Ishigami M; Murase K; Ito H; Ukai K; Yano M; Takagi K; Hattori M; Kakumu S; Yoshioka K
    Am J Gastroenterol; 2002 Apr; 97(4):988-98. PubMed ID: 12003437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic variability in hepatitis C virus and its role in antiviral treatment response.
    Torres-Puente M; Cuevas JM; Jiménez-Hernández N; Bracho MA; García-Robles I; Wrobel B; Carnicer F; Del Olmo J; Ortega E; Moya A; González-Candelas F
    J Viral Hepat; 2008 Mar; 15(3):188-99. PubMed ID: 18233992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.
    Hayashi K; Katano Y; Ishizu Y; Kuzuya T; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Gastroenterol Hepatol; 2015 Jan; 30(1):178-83. PubMed ID: 24995561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of positive selection in hepatitis C virus.
    Cuevas JM; Gonzalez M; Torres-Puente M; Jiménez-Hernández N; Bracho MA; García-Robles I; González-Candelas F; Moya A
    Infect Genet Evol; 2009 Sep; 9(5):860-6. PubMed ID: 19463971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus.
    Sáiz JC; López-Labrador FX; Ampurdanés S; Dopazo J; Forns X; Sánchez-Tapias JM; Rodés J
    J Infect Dis; 1998 Apr; 177(4):839-47. PubMed ID: 9534954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
    Yahoo N; Sabahi F; Shahzamani K; Malboobi MA; Jabbari H; Sharifi H; Mousavi-Fard SH; Merat S
    J Med Virol; 2011 Aug; 83(8):1332-7. PubMed ID: 21678437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients.
    Khorsi H; Castelain S; Wyseur A; Izopet J; Canva V; Rombout A; Capron D; Capron JP; Lunel F; Stuyver L; Duverlie G
    J Hepatol; 1997 Jul; 27(1):72-7. PubMed ID: 9252076
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential effect of interferon on hepatitis C virus 1b quasispecies in the nonstructural protein 5A gene.
    Sakuma I; Enomoto N; Kurosaki M; Izumi N; Marumo F; Sato C
    J Infect Dis; 1999 Oct; 180(4):1001-9. PubMed ID: 10479124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.